New warning label excluded from Zometa trial 
Published: April 18, 2011
Tags: Novartis, ONJ, osteonecrosis, product liability, Zometa
A product liability plaintiff could not introduce evidence that the defendant added a new warning label to the osteoporosis drug that allegedly injured her husband, a U.S. District Court in New York has ruled in granting a motion in limine.
Class action tolling preserves Zometa claim
By:
Pat Murphy
Published: January 14, 2011
Tags: class action, osteonecrosis, products liability, statute of limitations, Zometa
The doctrine of class action tolling applied to preserve the product liability lawsuit of a woman who claimed she suffered osteonecrosis of the jaw as a result of taking the prescription drug Zometa, the Montana Supreme Court has ruled.
Drug company hit with $13 million failure-to-warn verdict
By:
Sylvia Adcock
Published: December 3, 2010
Tags: Aredia, failure to warn, Novartis, osteonecrosis, product liability, Zometa
A federal jury in North Carolina has returned a verdict of nearly $13 million against pharmaceutical giant Novartis, saying the company failed to adequately warn patients and doctors about the risks of taking the bone-strengthening drugs Zometa and Aredia.
Zometa claims can go forward
By:
Pat Murphy
Published: March 13, 2010
Tags: Aredia, drug litigation, product liability, Zometa
A state presumption in favor of manufacturers does not apply to defeat product liability claims brought by plaintiffs who alleged they suffered severe jaw deterioration after taking the defendant’s bone-strengthening drugs, a U.S. District Court in Tennessee has ruled in denying a motion for summary judgment.
Woman awarded $3.2M in Zometa trial
By:
Pat Murphy
Published: October 22, 2009
Tags: product liability, Zometa
A Montana jury on Wednesday awarded $3.2 million to a woman suing the maker of a bone-strengthening drug in a decision that could have a bearing on hundreds of cases against the company nationwide.
Zometa trial could have national significance
By:
Pat Murphy
Published: October 19, 2009
Tags: Zometa
A lawsuit against a Swiss pharmaceutical company went to trial last week in Montana, but a verdict in the case could have national significance for hundreds of plaintiffs suing the company in a mass tort. Peggy L. Stevens of Missoula developed severe dental and jaw-related problems after taking Zometa, a bone-strengthening medication manufactured by Novartis. Her attorneys say the company knew patients taking Zometa were vulnerable to a degenerative jaw disorder called osteonecrosis, particularly those patients who undergo invasive dental procedures, like root canals or tooth extractions.
SUBSCRIBERS: Did you receive the new Lawyers USA Weekly Update in your inbox on Monday?
If not, click here to register and learn more now.
